HanAll, Daewoong to develop new drug for dry eyes
Mar 15, 2016
HanAll Biopharma and Daewoong Pharmaceutical have agreed to jointly develop a new drug to treat dry eye syndrome — a common eye condition in which insufficient tears are made to lubricate the eye. Under the agreement signed Monday, the two firms are set to develop HL036, a promising dry eye syndrome drug candidate developed by HanAll. HL036 is a biobetter — an improved version of an existing biopharmaceutical treatment — which consists of anti-TNF antibodies that have been reformulated for an